Key statistics dashboard for Rallybio Corporation (RLYB). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Stock Data
| Price | $17.09 |
| Market Cap | $91M |
| Beta | -1.20 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | 2.09 |
| Price / Book | 1.00 |
| P/S | 136.45 |
| P/FCF | 3.35 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -1107.59% |
| EBIT Margin | 4167.03% |
| EBITDA Margin | 4174.15% |
| Operating Margin | -3672.29% |
| Net Margin | 7051.24% |
Financial Health
| Current Ratio | 27.26 |
| Quick Ratio | 27.26 |
| Cash Ratio | 26.03 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -2.86 |
Per-Share Data
| Revenue per share | 0.11 |
| Book Value per share | 16.58 |
| Cash per share | 16.29 |
| FCF per share | 4.62 |
| Tangible Book Value per share | 16.58 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 5 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 9 |
| Avg rating (1-5) | 0.44 |
Related companies: BOLD · CVKD · IBIO · INTS · ITRM · KLTO · QTTB
Explore sector: Healthcare · Biotechnology
More sections of RLYB: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks